- In vitro test performed by an independent laboratory (Citech, Plymouth Meeting,
PA). Laboratory test results may not be indicative of clinical performance.
- Caridi J, Ross E, Aspilcueta A, Wiley S. The cannon-catheter-a prospective
analysis. J of Vasc and Interv
Radiol. 2010;21:1588-1590. The Arrow Edge®
Catheter is the antegrade version of and has the same tip design as the retrograde
Arrow® Cannon® Catheter. Both catheters
are designed for placement in the mid-right atrium.
- Alcohol, alcohol-based solutions (e.g., Hibiclens®,
ChloraPrep®), iodine-based solutions (Povidone-Iodine), PEG-based ointments
(e.g., Bactroban®), hydrogen peroxide or ExSept
Plus® are accepted for use with this catheter.
The Arrow Edge® catheter is indicated for use in attaining
long-term vascular access for hemodialysis and apheresis. The Arrow Edge® catheter is
inserted percutaneously and is preferentially placed into the internal jugular (IJ) vein.
Alternately, this catheter may be inserted into the subclavian vein although the jugular vein is the
preferred site. Catheters greater than 40 cm are intended for femoral vein insertion. Arrow
Edge® catheter is intended for use in adult patients.
Refer to the Instructions for Use for a complete listing of the indications, contraindications,
warnings and precautions. Information in this material is not a substitute for the product
Instructions for Use.
CAUTION: Federal (USA) law restricts this device to sale by or on the order of a physician.
Not all products are available in all regions. Please contact customer service to confirm
availability in your region.
Hibiclens is a registered trademark of Regent Medical Limited.
ChloraPrep is a registered trademark of Carefusion 2200, Inc.
Bactroban is a registered trademark of GlaxoSmithKline, LLC.
ExSept Plus is a registered trademark of Angelini Pharma, Inc.
Teleflex, the Teleflex logo, Arrow, Arrow Edge and SmartSeal are trademarks or registered trademarks
of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries. MC-004199 Rev 1